Search Immortality Topics:

Page 4«..3456..1020..»

Concise Report 2020: Agricultural Biotechnology Market Competitive Landscape and Industrial Growth| The Impact of COVID-19 Disruption During 2029 -…

Posted: May 28, 2020 at 11:45 am

Worldwide Agricultural Biotechnology Market, [Forecast 2020-2029] Succinct Study Report is in-depth survey on the current state of the global Agricultural Biotechnology industry with focus on short term and long term impact analysis of COVID-19/CORONAVIRUS. The report provides key statistics on the market status of the Agricultural Biotechnology manufacturers and is a valuable source of guidance and direction for companies and individuals interested in the industry.

The Agricultural Biotechnology Market report covers detailed competitive outlook including the market share and company profiles of the key participants operating in the global market. Vital key players profiled in the report include KWS SAAT SE & Co. KGaA, ChemChina, Limagrain, Nufarm, Marrone Bio Innovations, Performance Plants Inc., Corteva, ADAMA Ltd, MITSUI & CO., LTD, Evogene Ltd., Valent BioSciences LLC, Bayer AG. Company profile includes assign such as company summary, SWOT analysis and current developments, financial summary, product specifications, production value, business strategy and planning. This report analyzes the top players in global market, and splits the Agricultural Biotechnology market by application, organism type, and regions and countries.

|| Access insightful study with over 100+ pages, list of tables & figures, profiling 10+ companies. Ask for Free Sample Copy(PDF) @

Through the statistical analysis, the report depicts the global total market of the Agricultural Biotechnology industry including capacity, production value, cost/profit, supply/demand, production and import/export. The total market is further divided by company, by country, and by application/type for the competitive landscape analysis. The report then estimates the 2020-2029 market development trends of the Agricultural Biotechnology industry. Analysis of upstream raw materials, downstream demand and current market dynamics is also carried out in this report.

In the end, the report makes some important proposals for a new project of the Agricultural Biotechnology Industry before evaluating its feasibility. Overall, the report provides an in-depth insight into the 2020-2029 global Agricultural Biotechnology industry covering all important parameters.

The Final Report will cover the impact analysis of COVID-19 on this industry (Global and Regional Market).

>>>>Download Here- Short Term & Long Term Impact Analysis of Agricultural Biotechnology Market<<<<

Promising Regions & Countries Mentioned In The Agricultural Biotechnology Market Report:

North America (U.S. & Canada)

Latin America (Brazil, Mexico, Argentina, Rest of Latin America)

Europe (U.K., Germany, France, Italy, Spain, Hungary, Belgium, Netherlands & Luxembourg, NORDIC, Poland, Turkey, Russia, Rest of Europe)

Asia-Pacific (China, India, Japan, South Korea, Indonesia, Malaysia, Australia, New Zealand, Rest of Asia-Pacific)

The Middle East and Africa (Israel, GCC [Saudi Arabia, UAE, Bahrain, Kuwait, Qatar, Oman], North Africa, South Africa, Rest of The Middle East and Africa)

Years Considered For This Report:

Historical Years :2013-2018

Base Year :2019

Estimated Year :2020

Forecast Period: 2020-2029

A complete value chain of the global Agricultural Biotechnology Market is presented in the research report. It is associated with the review of the downstream and upstream components of the Agricultural Biotechnology Market. The market is bifurcated on the basis of the categories of products and the customer application segments. The market analysis demonstrates the expansion of each segment of the global Agricultural Biotechnology Market. The research report assists the user in taking a decisive step that will be a milestone in developing and expanding their businesses in the global Agricultural Biotechnology Market.

For any special requirements about this report[Click Here- For Enquiry & Report Customization]please let us know and we can provide custom reports.

Key Answers Captured in Report?

Which geography would have better demand for products/services?

What are the strategies adopted by big players in the regional market?

Which country would see the steep rise in CAGR & year-on-year (Y-O-Y) growth?

What is the current & expected market size in the next five years?

What is the market feasibility for long term investment?

What opportunity the country would offer for existing and new players in the market?

What is the risk involved for suppliers in the geography?

What factors would drive the demand for the product/service in the near future?

What is the impact analysis of various factors in market growth?

There Are 13 Chapters To Thoroughly Display The Agricultural Biotechnology Market:

Chapter 1:Global Agricultural Biotechnology Market Overview, Product Overview, Market Segmentation, Market Overview of Regions, Market Dynamics, Limitations, Opportunities and Industry News and Policies.

Chapter 2:Global Agricultural Biotechnology Market Chain Analysis, Upstream Raw Material Suppliers, Major Players, Production Process Analysis, Cost Analysis, Market Channels and Major Downstream Buyers.

Chapter 3:Value Analysis, Production, Growth Rate and Price Analysis by Type of Agricultural Biotechnology.

Chapter 4:Downstream Characteristics, Consumption and Market Share by Application of Agricultural Biotechnology.

Chapter 5:Production Volume, Price, Gross Margin, and Revenue ($) of Agricultural Biotechnology by Regions (2013-2020).

Chapter 6:Agricultural Biotechnology Production, Consumption, Export and Import by Regions (2013-2020).

Chapter 7:Agricultural Biotechnology Market Status and SWOT Analysis by Regions.

Chapter 8:Global Competitive Landscape, Product Introduction, Company Profiles, Market Distribution Status by Players of Agricultural Biotechnology.

Chapter 9:Agricultural Biotechnology Market Analysis and Forecast by Type and Application (2020-2029).

Chapter 10:Global Market Analysis and Forecast by Regions (2020-2029).

Chapter 11:Global Industry Characteristics, Key Factors, New Entrants SWOT Analysis, Investment Feasibility Analysis.

Chapter 12:Market Conclusion of the Whole Report.

Chapter 13:Appendix Such as Methodology and Data Resources of This Research

....For Detailed InformationClick Here For Complete TOC

Why MarketResearch.Biz?

Robust research methodology of Agricultural Biotechnology market

Technically renowned study with overall Agricultural Biotechnology industry know-how

Focus on Agricultural Biotechnology drivers, restraints, opportunities, and threats till 2029

Based on complete research, we offer the clear view of real Agricultural Biotechnology market scenario and help clients with making an important business judgment

A comprehensive archive of Agricultural Biotechnology market research reports to meet our clients needs

Contact Us:

Mr. Benni Johnson ([emailprotected])

MarketResearch.Biz (Powered By Prudour Pvt. Ltd.)

420 Lexington Avenue, Suite 300

New York City, NY 10170,

United States


Go here to read the rest:
Concise Report 2020: Agricultural Biotechnology Market Competitive Landscape and Industrial Growth| The Impact of COVID-19 Disruption During 2029 -...

Recommendation and review posted by G. Smith

Global Biotechnology Market North America is expected to account for higher market share of more than… – Azizsalon News

Posted: May 28, 2020 at 11:45 am

Global Biotechnology Market is expected to grow at a CAGR of 14% to reach US$ XX million in 2026.

The growth is coupled with rising demand of modern and innovative technologies such as DNA sequencing, recombinant technology, fermentation, tissue engineering. Further, rising demand for food to meet the need of ever increasing population and scarce availability of non-renewable natural resources also expected to drive the biotechnology market. Application of Genetic engineering and Genetic Modification (GM) processes to agricultural food products also expected to drive the business growth. Furthermore, decreasing prices of DNA sequencing technologies will encourage R&D activities to better understand genetic variations and develop therapeutic solutions.


Moreover, development of novel techniques and their implementation by the organisation by collaborating with the other participants will drive the Global Biotechnology Market. Further, increasing demand for therapeutic and diagnostic solutions on principles of red biotechnology, DNA sequencing, and recombinant technology is expected to drive the Global Biotechnology Market through 2024. Increasing prevalence of diseases such as hepatitis B, cancer, and other orphan disorders is also expected to fuel demand in the forecast period.

In 2017, North America dominated the overall market. The market growth is driven by the increasing R&D investments relating to new drug discovery and development. U.S. held highest market in North America due to increasing level of per capita spending on healthcare than other countries and has a high growth rate amongst other countries. According to the estimates published by OECD Health Statistics in 2014, it has been estimated that in 2012, U.S. spent nearly 16.9% of its GDP towards healthcare expenditure, which is the highest. The fact supports the estimated share of Global Biotechnology Market.

Asia Pacific is expected to have higher growth rate in the forecast period owing to the presence of patient awareness, rapidly improving healthcare infrastructure, and rising healthcare expenditure levels in the emerging markets. Global Biotechnology Market include the developing economies of China and India.

In 2017, nanobiotechnology held the highest market share. The Global Biotechnology Market growth is driven by fermentation and cell-based assay segments owing to rising R&D initiatives by various biotechnological and pharmaceutical companies.

The objective of the report is to present comprehensive Global Biotechnology Market including all the stakeholders of the industry. The past and current status of the industry with forecasted market size and trends are presented in the report with analysis of complicated data in simple language. The report covers all the aspects of industry with dedicated study of key players that includes market leaders, followers and new entrants by region. PORTER, SVOR, PESTEL analysis with the potential impact of micro-economic factors by region on the market have been presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analyzed, which will give clear futuristic view of the industry to the decision makers.

The report also helps in understanding Global Biotechnology Market North America for Asia Pacific dynamics, structure by analyzing the market segments, and project the Global Biotechnology Market North America for Asia Pacific size. Clear representation of competitive analysis of key players by type, price, financial position, product portfolio, growth strategies, and regional presence in the Global Biotechnology Market North America for Asia Pacific make the report investors guide.


Market SegmentationGlobal Biotechnology Market, By Technologyo DNA Sequencingo Nanobiotechnologyo Tissue engineering and Regenerationo Fermentationo Cell Based Assayo PCR Technologyo Chromatography Marketo Others

Global Biotechnology Market, By Applicationso Healtho Food & Agricultureo Natural Resources & Environmento Industrial Processingo Bioinformaticso Others

The above data will be provided for following regions/countries from 2013-2024 (USD Million)

North Americao U.S.o Canada

Europeo Germanyo UKo Franceo Spaino Italy

Asia Pacifico Chinao Indiao Japano Australia

Latin Americao Argentinao Brazilo Mexico

Middle East and Africao South Africao Saudi Arabia


Chapter One: Biotechnology Market Overview

Chapter Two: Manufacturers Profiles

Chapter Three: Global Biotechnology Market Competition, by Players

Chapter Four: Global Biotechnology Market Size by Regions

Chapter Five: North America Biotechnology Revenue by Countries

Chapter Six: Europe Biotechnology Revenue by Countries

Chapter Seven: Asia-Pacific Biotechnology Revenue by Countries

Chapter Eight: South America Biotechnology Revenue by Countries

Chapter Nine: Middle East and Africa Revenue Biotechnology by Countries

Chapter Ten: Global Biotechnology Market Segment by Type

Chapter Eleven: Global Biotechnology Market Segment by Application

Chapter Twelve: Global Biotechnology Market Size Forecast (2019-2026)

Browse Full Report with Facts and Figures of Biotechnology Market Report at:

About Us:

Maximize Market Research provides B2B and B2C market research on 20,000 high growth emerging technologies & opportunities in Chemical, Healthcare, Pharmaceuticals, Electronics & Communications, Internet of Things, Food and Beverages, Aerospace and Defense and other manufacturing sectors.

Contact info:

Name: Vikas Godage



Contact: +919607065656/ +919607195908

More here:
Global Biotechnology Market North America is expected to account for higher market share of more than... - Azizsalon News

Recommendation and review posted by G. Smith

AXONIS Therapeutics, Inc. Announces Seed Financing for Preclinical Development of Neuromodulating KCC2 Therapy – Business Wire

Posted: May 28, 2020 at 11:45 am

CAMBRIDGE, Mass,--(BUSINESS WIRE)--AXONIS Therapeutics, Inc., an emerging biotechnology company advancing breakthrough research to treat spinal cord injury and paralysis, today announced the close of the first tranche of a $4 million Seed Preferred financing. The financing was led by Kerry Murphy, an investor, philanthropist and AXONIS Board member. The funds will enable AXONIS to conduct pre-clinical studies on its novel technology that reactivates spared neural tissue at the spinal cord injury site through upmodulation of the KCC2 protein activity. The importance of KCC2 treatment in recovery of stepping ability was first discovered by Dr. Zhigang He in his lab at Boston Childrens Hospital.

We are very pleased with this seed funding, as it will allow us to initiate important pre-clinical work and build our team as we advance this technology, said Joanna Stanicka, PhD, CEO, AXONIS Therapeutics. We have seen very promising results in the proof-of-concept studies thus far, and look forward to moving this critical research to the next stage in our mission to treat paralysis.

Many years in academia, biotechnology and pharma have given me the experience and perspective to recognize the importance of Dr. Hes discovery and what AXONIS is aiming to achieve, said Corey Goodman, PhD, Executive Chair and co-founder of AXONIS. That background underscores my excitement in AXONIS neuromodulating therapy not only for spinal cord injury, the initial focus, but also other neurological disorders, such as epilepsy, where it also has major potential.

The second tranche of the financing will be provided following the Companys successful delivery of proof-of-concept data, which is expected in approximately one year. The financing follows the strengthening of the leadership team including the appointment of Dr. Stanicka as CEO in October 2019, along with an expanded Board of Directors. Under the new leadership, AXONIS received state and federal non-dilutive funding and other seed investment. Dr. Stanicka also won a Boehringer Ingelheim Golden Ticket that provides one year of free lab space at LabCentral in Cambridge.

AXONIS has licensed or optioned two technologies from Boston Childrens Hospital, the leading pediatric hospital in the world. In addition to its primary work on the KCC2 protein, AXONIS has also been investigating PTEN inhibition to help regenerate nerve connections after injury. Through tissue reactivation and nerve regeneration, AXONIS is focused on identifying effective therapies to restore movement in paralyzed patients after spinal cord injury.

Spinal cord injury causes devastating paralysis, loss of sensation and loss of other bodily functions below the level of the injury. Across the US, Canada and Western Europe, it is estimated that there are more than 3.6 million cases, and more than 180,000 new cases each year, with each SCI patient requiring more than $100,000, on average, in annual care.

AXONIS Science Advisory Council includes Oswald Steward, PhD, Director of the Reeve-Irvine Research Center at the University of California at Irvine; Lisa McKerracher, PhD, CEO, BioAxone BioSciences, Inc.; and Dr. Goodman, Managing Partner, venBio Partners.

AXONIS was founded by Bob Yant, a well-known advocate for spinal cord regeneration research. Following a 1981 accident that left Bob a quadriplegic, he has dedicated significant time to raising funds for basic research aimed at developing a cure for spinal cord injury. Bob is a former Director of the Christopher and Dana Reeve Foundation, and Founder of Cure Medical.

About AXONIS Therapeutics

AXONIS Therapeutics, Inc. is a biotechnology company based in Cambridge, MA, committed to developing groundbreaking therapies for spinal cord injury, and other currently incurable neurological disorders. AXONIS is advancing two breakthrough discoveries, KCC2 upmodulation to reactivate spared tissue and PTEN inhibition to regenerate injured nerve connections, to make a real difference for patients, their families, and the global healthcare system. For more information, visit

The rest is here:
AXONIS Therapeutics, Inc. Announces Seed Financing for Preclinical Development of Neuromodulating KCC2 Therapy - Business Wire

Recommendation and review posted by G. Smith

Rebranding: ITG Isotope Technologies Garching GmbH will become ITM Medical Isotopes GmbH – Business Wire

Posted: May 28, 2020 at 11:45 am

GARCHING & MUNICH, Germany--(BUSINESS WIRE)--ITM Isotopen Technologien Mnchen AG (ITM), a biotechnology and radiopharmaceutical group of companies, today announced the change of name of its subsidiary ITG Isotope Technologies Garching GmbH. With effect from May 28, 2020, the company responsible specifically for the production of medical isotopes within the ITM Group will operate under the name ITM Medical Isotopes GmbH. The background to the decision is to present a uniform external image of the ITM group of companies, which, alongside ITM Medical Isotopes GmbH, includes among others the highly specialized companies ITM Oncologics GmbH and ITM Solucin GmbH.

The change of name will have no other impact on business partners, customers and staff. The legal form of the company and the ownership structure will remain unchanged. The fields of activity of radioisotope production, the product portfolio and all contracts concluded up to the rebranding will remain unchanged under the new company name. The head office address, the commercial register number and all known contact partners will remain unchanged.

ITG Isotope Technologies Garching GmbH, or ITM Medical Isotopes GmbH, is a 100% subsidiary of ITM Isotopen Technologien Mnchen AG. Over the course of the companys 16-year history, from a start-up housed on the Technical University of Munich (TUM) site, ITM has established itself as a worldwide biotechnology and radiopharmaceutical group of companies in Targeted Radionuclide Therapy with a global distribution network. ITM develops, produces and distributes radiopharmaceuticals and medical radioisotopes for the diagnosis and therapy of cancer. The current product portfolio and focus of research includes targeted candidates for the treatment of neuroendocrine tumors, glioblastoma, osteosarcoma and bone metastases, as well as folate receptor positive tumors such as lung, ovarian or breast cancer.

We are proud of everything that we have managed to achieve jointly as the ITM group of companies over the past 16 years. We now supply hospitals, and hence patients, worldwide with our radiopharmaceuticals and medical radioisotopes for targeted cancer therapy, says Steffen Schuster, CEO of ITM. The pooling of our subsidiaries expertise will now also be reflected nominally by the unification under the ITM family brand. This will strengthen our market position and will allow all business areas to benefit equally from our first-class reputation as an international biotechnology and radiopharmaceutical group of companies, adds Steffen Schuster, CEO of ITM.

- End -

Read more from the original source:
Rebranding: ITG Isotope Technologies Garching GmbH will become ITM Medical Isotopes GmbH - Business Wire

Recommendation and review posted by G. Smith

Where Does Cara Therapeutics Inc (CARA) Stock Fall in the Biotechnology Field? – InvestorsObserver

Posted: May 28, 2020 at 11:45 am

Cara Therapeutics Inc (CARA) is near the middle in its industry group according to InvestorsObserver. CARA gets an overall rating of 62. That means it scores higher than 62 percent of stocks. Cara Therapeutics Inc gets a 53 rank in the Biotechnology industry. Biotechnology is number 8 out of 148 industries.

Finding the best stocks can be tricky. It isnt easy to compare companies across industries. Even companies that have relatively similar businesses can be tricky to compare sometimes. InvestorsObservers tools allow a top-down approach that lets you pick a metric, find the top sector and industry and then find the top stocks in that sector.

These scores are not only easy to understand, but it is easy to compare stocks to each other. You can find the best stock in an industry, or look for the sector that has the highest average score. The overall score is a combination of technical and fundamental factors that serves as a good starting point when analyzing a stock. Traders and investors with different goals may have different goals and will want to consider other factors than just the headline number before making any investment decisions.

Cara Therapeutics Inc (CARA) stock is lower by -1.23% while the S&P 500 has gained 0.62% as of 2:19 PM on Wednesday, May 27. CARA has fallen -$0.20 from the previous closing price of $16.31 on volume of 372,663 shares. Over the past year the S&P 500 is higher by 7.42% while CARA has fallen -10.40%. CARA lost -$2.55 per share the over the last 12 months.

To see InvestorsObserver's Sentiment Score for Cara Therapeutics Inc click here.

See more here:
Where Does Cara Therapeutics Inc (CARA) Stock Fall in the Biotechnology Field? - InvestorsObserver

Recommendation and review posted by G. Smith

Red Biotechnology Market Research, Recent Trends and Growth Forecast 2025 – ZZReport

Posted: May 28, 2020 at 11:45 am

A Research study on Red Biotechnology Market analyzes and offers ideas of exhaustive research on ancient and recent Red Biotechnology market size. Along with the estimated future possibilities of the market and emerging trends in the Red Biotechnology market.

Request Sample Copy of this Report @

The report on Red Biotechnology market is an all-inclusive study of the current scenario of the industry and its growth prospects over 2025. The report is a meticulous endeavor to present a comprehensive overview of Red Biotechnology market based on growth opportunities and market shares. The report presents a detailed outline of the product type, key manufacturers, application and key regions concerned in the Red Biotechnology market.

This report considers various parameters to calculate the Red Biotechnology market size especially, value and volume generated from the sales in such segments as product type, application, region, competitive landscape etc.

The competitive scenario of the Red Biotechnology market has also been evaluated by the report while presenting detailed analysis of notable manufacturers and vendors participating in the Red Biotechnology market.

Major companies covered in the Red Biotechnology market report are as follows:

Red Biotechnology market has been segmented by product type as follow:

Antibody, Nucleic Acid, Protein and Other

Red Biotechnology market has been segmented by application type as follow:

Biopharmaceutical Production, Gene Therapy and Pharmacogenomics and Genetic Testing

Additionally, the report discusses key trends driving the growth of the market, opportunities involved, major challenges and risks that are often confronted by key manufacturers besides presenting an overall idea of the market. The report also analyses in details emerging trends in the marketplace and their impact on current and future development of the Red Biotechnology market.

Research objectives of the study included the analysis of global Red Biotechnology market consumption in terms of volume and value based on parameters such as regions, application and product type based on data and forecast for the period of 2025. In an effort to describe, define and analyze the volume, value, market share, sales, competitive landscape, development plans and SWOT analysis for the ensuing years, the report focuses on key manufacturers and their actions in Red Biotechnology market.

The report analyses Red Biotechnology in respect to growth trends, future prospects and contribution of individual players in the Red Biotechnology market. It also reveals detailed information about the growth potential, drivers, opportunities, risks and challenges that influence the development of Red Biotechnology market. The report presents a comprehensive projection of the regional submarkets of Red Biotechnology along with the key countries where the submarkets are most dominant. It also analyses developments such as new product launches, agreements, acquisitions and expansions as well as provides strategic profiles of key players in Red Biotechnology market while highlighting their growth strategies.

An overview of Red Biotechnology market segmentation

Request Customization on This Report @

Read the original:
Red Biotechnology Market Research, Recent Trends and Growth Forecast 2025 - ZZReport

Recommendation and review posted by G. Smith

Page 4«..3456..1020..»